Proginorm Ovo 200mg 30 capsules — Made in Spain — Free Delivery

Brand: Laboratorios Leon Farma
Product Code: Proginorm Ovo
Availability: In Stock

$61.70

Add to Cart

Description

Product description

Progynorm Ovo capsules are used for the following indications:

gynecological:

disorders associated with progesterone deficiency, namely: premenstrual syndrome, menstrual disorders (dysovulation, anovulation), fibrocystic mastopathy, premenopausal period;
hormone replacement therapy in menopause (in combination with estrogen therapy);
infertility with luteal insufficiency;

obstetric:

prevention of habitual miscarriage or the threat of miscarriage on the background of luteal insufficiency;
risk of preterm birth.

Compound

Active ingredient - progesterone (one soft capsule contains progesterone 200 mg).

Excipients: peanut oil, soy lecithin; capsule shell: gelatin 150 Bloom, glycerin 99%, titanium dioxide (E171).

Contraindications

hypersensitivity to the components of the preparation;
severe liver dysfunction;
suspected or confirmed neoplasia of the breast or genital organs;
undiagnosed vaginal bleeding;
unsuccessful or incomplete abortion;
thrombophlebitis, rhomboembolic disorders;
hemorrhage in the brain;
porphyria.

Mode of application

It is recommended to take the capsules with a glass of water on an empty stomach, preferably in the evening, before going to bed.

In most cases, the average daily dose is 200-300 mg in 1 or 2 doses (200 mg in the evening, before bedtime, and 100 mg in the morning, if necessary).

In case of insufficiency of the luteal phase (premenstrual syndrome, menstrual irregularities, premenopause, fibrocystic mastopathy): take for 10 days (usually from the 17th to the 26th day of the cycle inclusive).

In menopausal hormone replacement therapy: since estrogen therapy alone is not recommended, progesterone should be used as an adjunct to it for the last two weeks of each course, which follows the one-week support of any replacement therapy during which withdrawal bleeding may occur.

With the threat of preterm birth: take 400 mg of the preparation "Proginorm Ovo" every 6-8 hours until the symptoms disappear. An effective dose and frequency of use are selected individually, depending on the clinical manifestations of the threat of preterm birth. After the disappearance of symptoms, the dose of Progynorm Ovo is gradually reduced to a maintenance dose (for example, 200 mg 3 times a day). At this dose, the preparation can be used up to 36 weeks of pregnancy.

The use of progesterone after the 36th week of pregnancy is not recommended.

Application features

pregnant

The use of Progynorm Ovo capsules is not contraindicated during pregnancy, including in the first weeks. During the period of use of the preparation, not a single case of adverse effects of the preparation on the fetus was observed. When using the preparation in the second and third trimesters of pregnancy, monitoring of liver function is necessary.

Progesterone excretion into breast milk has not been studied in detail. Therefore, its administration should be avoided during breastfeeding.

There is evidence of the possible development of hypospadias when progestogens are used during pregnancy to prevent a typical miscarriage, or a threatened miscarriage due to luteal insufficiency, which the patient should be informed about.

Children

The preparation is not intended for use in pediatric practice.

Drivers

Transport drivers and machine operators: drowsiness and dizziness associated with taking the preparation internally are possible.

The use of capsules at bedtime avoids these unpleasant consequences.

Overdose

Symptoms of an overdose may be manifested by symptoms of adverse reactions, including drowsiness, dizziness, euphoria, dysmenorrhea, a decrease in the duration of the cycle, metrorrhagia.

In some individuals, the usual dose may be excessive due to the existing or secondary occurrence of unstable endogenous progesterone secretion, hypersensitivity to the preparation, or very low concomitant blood levels of estradiol.

In such cases, it is enough:

reduce the dose of progesterone or prescribe progesterone in the evening before bedtime for 10 days per cycle in case of drowsiness or transient dizziness;

postpone the start of treatment to a later date in the cycle (for example, the 19th day instead of the 17th) in case of its reduction or bleeding;

check whether the level of estradiol is sufficient in a patient who is receiving premenopausal hormone replacement therapy.

Side effects

Disorders of the reproductive system and mammary glands: frequent - change in menstruation, amenorrhea, intermittent bleeding; infrequent - mastodynia.

Disorders of the central nervous system: frequent - headaches; infrequent - drowsiness, short-term feeling of dizziness; very rare - depression.

Gastrointestinal disorders: infrequent - vomiting, diarrhea, constipation; rare - nausea.

Hepatobiliary disorders: infrequent - cholestatic jaundice.

Immune system disorders: very rare - urticaria.

Diseases of the skin and subcutaneous tissue: infrequent - itching, acne; very rare - chloasma.

There may also be manifestations of adverse reactions such as changes in libido, chest discomfort, premenstrual symptoms, hyperthermia, insomnia, alopecia, hirsutism, venous thromboembolism, pulmonary embolism, fluid retention, weight change, gastrointestinal disorders, anaphylactic reactions.

Drowsiness and / or dizziness are observed in case of concomitant hypoestrogenism. Reducing the dose of the preparation or increasing the dose of estrogen immediately eliminates these phenomena without reducing the therapeutic effect.

If the course of treatment is started very early in the beginning of the monthly cycle, especially before the 15th day, shortening of the cycle or occasional bleeding may occur.

Storage conditions

Store in the original packaging at a temperature not exceeding 25°C, out of the reach of children.

Shelf life - 3 years.

0 reviews

There are no reviews for this product.